Hillstream BioPharma, Inc. to Present at Upcoming Investor Conferences

Rhea-AI Summary

Hillstream BioPharma, Inc. (Nasdaq: HILS) announced that CEO Randy Milby will present and hold one-on-one meetings at two upcoming conferences: the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022, and the ThinkEquity Conference on October 26, 2022. The company focuses on developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism. Hillstream's leading drug candidate, HSB-1216, showed efficacy in treating severe cancers and aims to begin discussions with the FDA in early 2023.

BRIDGEWATER, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”), a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging anti-cancer mechanism resulting in iron-mediated cell death for drug resistant and devastating cancers, today announced that Randy Milby, Founder and Chief Executive Officer will present in-person and host one-on-one meetings with investors at the following conferences:

Event: Dawson James Securities 7^th Annual Small Cap Growth Conference
Date: Wednesday, October 12, 2022
Webcast: Conference Registration Link
Archived Recording: ir.hillstreambio.com
Time: Please check with the conference coordinator as presentation times are subject to change.
Location: Wyndham Grand Hotel in Jupiter, Florida

Event: ThinkEquity Conference
Date: Wednesday, October 26, 2022
Webcast: Conference Registration Link
Archived Recording: ir.hillstreambio.com
Time: Please check with the conference coordinator as presentation times are subject to change.
Location: The Mandarin Oriental Hotel in New York

About Hillstream BioPharma Inc.
Hillstream BioPharma, Inc. is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron mediated cell death for drug resistant and devastating cancers. Hillstream’s most advanced candidate is HSB-1216, an IMCD modulator, targeting a variety of solid tumors. The active drug in HSB-1216 was found to be efficacious in a clinical pilot study in Germany in devastating cancers, including triple negative breast cancer and epithelial carcinomas. Hillstream intends to initiate IND discussions with the FDA in first half of 2023. Hillstream uses Quatramer™, our proprietary tumor targeting platform, to enhance the uptake of HSB-1216 in the tumor microenvironment with an extended duration of action and minimal off-target toxicity. For more information, please visit www.hillstreambio.com.

Investor Contact:
investorrelations@hillstreambio.com

FAQ

What will Hillstream BioPharma present at the Dawson James Securities Conference?

Hillstream BioPharma will present its therapeutic candidates targeting ferroptosis and discuss the efficacy of HSB-1216 at the Dawson James Securities Conference on October 12, 2022.

When is the ThinkEquity Conference for Hillstream BioPharma?

The ThinkEquity Conference for Hillstream BioPharma is scheduled for October 26, 2022.

What is the primary focus of Hillstream BioPharma's research?

Hillstream BioPharma focuses on developing novel therapeutic candidates that target ferroptosis, aiming to treat drug-resistant and aggressive cancers.

What is HSB-1216 and its significance?

HSB-1216 is Hillstream's leading drug candidate that has shown efficacy in treating severe cancers, including triple negative breast cancer, and targets the tumor microenvironment.

When does Hillstream plan to start discussions with the FDA?

Hillstream BioPharma intends to initiate IND discussions with the FDA in the first half of 2023.